These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 25621996

  • 21. Combined radionuclide-chemotherapy and in vivo imaging of hepatocellular carcinoma cells after transfection of a triple-gene construct, NIS, HSV1-sr39tk, and EGFP.
    Lee YL, Lee YJ, Ahn SJ, Choi TH, Moon BS, Cheon GJ, Lee SW, Ahn BC, Ha JH, Lee J.
    Cancer Lett; 2010 Apr 01; 290(1):129-38. PubMed ID: 19819065
    [Abstract] [Full Text] [Related]

  • 22. Sodium-iodine symporter gene expression controlled by the EGR-1 promoter: biodistribution, imaging and in vitro radionuclide therapy with Na(131)I.
    Tang J, Wang X, Xu Y, Shi Y, Liu Z, Yang Y.
    Technol Cancer Res Treat; 2015 Feb 01; 14(1):61-9. PubMed ID: 24354753
    [Abstract] [Full Text] [Related]

  • 23. Image-guided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression.
    Spitzweg C, Baker CH, Bergert ER, O'Connor MK, Morris JC.
    Hum Gene Ther; 2007 Oct 01; 18(10):916-24. PubMed ID: 17931047
    [Abstract] [Full Text] [Related]

  • 24. Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene.
    Kim YH, Youn H, Na J, Hong KJ, Kang KW, Lee DS, Chung JK.
    Theranostics; 2015 Oct 01; 5(1):86-96. PubMed ID: 25553100
    [Abstract] [Full Text] [Related]

  • 25. Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: a novel therapeutic agent allowing noninvasive imaging and radioiodine therapy.
    Reddi HV, Madde P, McDonough SJ, Trujillo MA, Morris JC, Myers RM, Peng KW, Russell SJ, McIver B, Eberhardt NL.
    Cancer Gene Ther; 2012 Sep 01; 19(9):659-65. PubMed ID: 22790962
    [Abstract] [Full Text] [Related]

  • 26. Complementary treatment of siTERT for improving the antitumor effect of TERT-specific I-131 therapy.
    Kim S, Youn H, Song MG, Kang JH, Chung HK, Lee DS, Chung JK.
    Cancer Gene Ther; 2012 Apr 01; 19(4):263-70. PubMed ID: 22301953
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effective control of tumor growth through spatial and temporal control of theranostic sodium iodide symporter (NIS) gene expression using a heat-inducible gene promoter in engineered mesenchymal stem cells.
    Tutter M, Schug C, Schmohl KA, Urnauer S, Schwenk N, Petrini M, Lokerse WJM, Zach C, Ziegler S, Bartenstein P, Weber WA, Wagner E, Lindner LH, Nelson PJ, Spitzweg C.
    Theranostics; 2020 Apr 01; 10(10):4490-4506. PubMed ID: 32292510
    [Abstract] [Full Text] [Related]

  • 29. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
    Mitrofanova E, Unfer R, Vahanian N, Link C.
    Gene Ther; 2006 Jul 01; 13(13):1052-6. PubMed ID: 16525480
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Baculovirus vector-mediated transfer of sodium iodide symporter and plasminogen kringle 5 genes for tumor radioiodide therapy.
    Zhang M, Guo R, Shi S, Miao Y, Zhang Y, Li B.
    PLoS One; 2014 Jul 01; 9(3):e92326. PubMed ID: 24647588
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Application of 188rhenium as an alternative radionuclide for treatment of prostate cancer after tumor-specific sodium iodide symporter gene expression.
    Willhauck MJ, Sharif Samani BR, Gildehaus FJ, Wolf I, Senekowitsch-Schmidtke R, Stark HJ, Göke B, Morris JC, Spitzweg C.
    J Clin Endocrinol Metab; 2007 Nov 01; 92(11):4451-8. PubMed ID: 17698909
    [Abstract] [Full Text] [Related]

  • 35. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter-driven expression of the human sodium-iodide symporter.
    Chen RF, Li ZH, Pan QH, Zhou JJ, Tang QB, Yu FY, Zhou QB, Wang J, Chen JS.
    Pancreatology; 2007 Nov 01; 7(5-6):505-13. PubMed ID: 17912014
    [Abstract] [Full Text] [Related]

  • 36. Adenovirus-mediated and targeted expression of the sodium-iodide symporter permits in vivo radioiodide imaging and therapy of pancreatic tumors.
    Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC.
    Hum Gene Ther; 2006 Jun 01; 17(6):661-8. PubMed ID: 16776574
    [Abstract] [Full Text] [Related]

  • 37. Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.
    Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.
    Oncotarget; 2017 May 16; 8(20):33393-33404. PubMed ID: 28380420
    [Abstract] [Full Text] [Related]

  • 38. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer.
    Scholz IV, Cengic N, Baker CH, Harrington KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC, Spitzweg C.
    Gene Ther; 2005 Feb 16; 12(3):272-80. PubMed ID: 15510175
    [Abstract] [Full Text] [Related]

  • 39. Establishment and characterization of a breast cancer cell line expressing Na+/I- symporters for radioiodide concentrator gene therapy.
    Nakamoto Y, Saga T, Misaki T, Kobayashi H, Sato N, Ishimori T, Kosugi S, Sakahara H, Konishi J.
    J Nucl Med; 2000 Nov 16; 41(11):1898-904. PubMed ID: 11079502
    [Abstract] [Full Text] [Related]

  • 40. In vivo long-term imaging and radioiodine therapy by sodium-iodide symporter gene expression using a lentiviral system containing ubiquitin C promoter.
    Kim HJ, Jeon YH, Kang JH, Lee YJ, Kim KI, Chung HK, Jeong JM, Lee DS, Lee MC, Chung JK.
    Cancer Biol Ther; 2007 Jul 16; 6(7):1130-5. PubMed ID: 17611400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.